135 related articles for article (PubMed ID: 27743987)
1. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
Deuffic-Burban S; Boursier J; Leroy V; Yazdanpanah Y; Castera L; Mathurin P
J Hepatol; 2017 Feb; 66(2):304-312. PubMed ID: 27743987
[TBL] [Abstract][Full Text] [Related]
2. Predicted effects of treatment for HCV infection vary among European countries.
Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and natural history of hepatitis C virus infection among children and young people.
Modin L; Arshad A; Wilkes B; Benselin J; Lloyd C; Irving WL; Kelly DA
J Hepatol; 2019 Mar; 70(3):371-378. PubMed ID: 30496763
[TBL] [Abstract][Full Text] [Related]
5. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage: a hospital-based linkage study.
Huang Y; de Boer WB; Adams LA; MacQuillan G; Bulsara MK; Jeffrey GP
Intern Med J; 2015 Jan; 45(1):48-54. PubMed ID: 25371273
[TBL] [Abstract][Full Text] [Related]
8. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
9. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
[TBL] [Abstract][Full Text] [Related]
10. Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study.
K-Kutala B; Bedossa P; Guedj J; Asselah T; Martinot-Peignoux M; Duval X; Marcellin P
Dig Liver Dis; 2015 Apr; 47(4):296-302. PubMed ID: 25596930
[TBL] [Abstract][Full Text] [Related]
11. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
[TBL] [Abstract][Full Text] [Related]
12. Estimates on HCV disease burden worldwide - filling the gaps.
Wedemeyer H; Dore GJ; Ward JW
J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
Dore GJ; Ward J; Thursz M
J Viral Hepat; 2014 May; 21 Suppl 1():1-4. PubMed ID: 24713003
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment.
Stasi C; Sadalla S; Carradori E; Monti M; Petraccia L; Madia F; Gragnani L; Zignego AL
Curr Med Res Opin; 2020 Feb; 36(2):245-249. PubMed ID: 31702411
[No Abstract] [Full Text] [Related]
15. [Histological findings in the liver in patients with chronic hepatitis C].
Takase K; Shiraki K
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):434-8. PubMed ID: 15359838
[No Abstract] [Full Text] [Related]
16. [Chronic hepatitis C].
Grammatikos G; Sarrazin C
Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
Zarski JP; Sturm N; Desmorat H; Melin P; Raabe JJ; Bonny C; Sogni P; Pinta A; Rouanet S; Babany G; Cheveau A; Chevallier M
Liver Int; 2010 Aug; 30(7):1049-58. PubMed ID: 20492512
[TBL] [Abstract][Full Text] [Related]
18. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.
Deuffic-Burban S; Mathurin P; Rosa I; Bouvier AM; Cannesson A; Mourad A; Canva V; Louvet A; Deltenre P; Boleslawski E; Truant S; Pruvot FR; Dharancy S
Dig Liver Dis; 2014 Feb; 46(2):157-63. PubMed ID: 24119483
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
20. New developments in the antiviral treatment of hepatitis C.
de Bruijne J; Weegink CJ; Jansen PL; Reesink HW
Vox Sang; 2009 Jul; 97(1):1-12. PubMed ID: 19392783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
